基于AHP-TOPSIS法评价聚乙二醇化重组人粒细胞刺激因子合理应用情况

Evaluation of rational application of pegylated recombinant human granulocyte colony-stimulating factor based on AHP-TOPSIS method

摘要:

目的 建立聚乙二醇化重组人粒细胞刺激因子（PEG-rhG-CSF）合理评价体系，为评价PEG-rhG-CSF应用合理性提供参考。方法 以PEG-rhG-CSF药品说明书、相关指南等为依据，制定PEG-rhG-CSF应用合理性评价细则，通过层次分析法（AHP）计算各评价指标权重，采用优劣解距离法（TOPSIS）对广州市第一人民医院2021年1月—6月使用PEG-rhG-CSF的肿瘤患者进行药物使用合理性分析。结果 建立包括3个一级指标和10个二级指标的评价体系。在纳入的612份病例中，用药完全合理占28.76%，基本合理占55.23%，不合理占16.01%。结论 该院PEG-rhG-CSF的应用基本合理，但在给药时机、给药适应证、给药剂量上仍存在较大的不合理性，需进一步改善。

Abstract:

Objective To establish an evaluation system for rational use of pegylated recombinant human granulocyte colony-stimulating factor(PEG-rhG-CSF), and to provide reference for evaluating the rational application of PEG-rhG-CSF.Methods The detailed evaluation rules for rational use of PEG-rhG-CSF were formulated on the base of PEG-rhG-CSF instructions, related guidelines and so on. The weight of each evaluation index was calculated through analytical hierarchy process (AHP). The technique for order preference by similarity to ideal solution (TOPSIS) was also used to analyze the rational use of PEG-rhG-CSF among the tumor patients treated between January 2021 and June 2021 in Guangzhou First People's Hospital.Results The evaluation system was established, including 3 primary indicators and 10 secondary indicators. In the included 612 cases, the cases with completely rational use of PEG-rhG-CSF accounted for 28.76%, and those with basically rational use of PEG-rhG-CSF accounted for 55.23%, while 16.01% of them had unreasonable use of PEG-rhG-CSF.Conclusion Through the rationality evaluation with AHP-TOPSIS method, it is found that the use of PEG-rhG-CSF in the hospital was generally reasonable, but there were still significant inadequacies in terms of administration timing, indications, and dosage, which require further improvement.